 |
|
Hypertriglyceridemia and Its Pharmacologic Treatment Among US Adults—Invited Commentary
Warren G. Thompson, MD;
Gerald T. Gau, MD
Arch Intern Med. 2009;169(6):578-579.
|
|
| Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings. |
|
|
|
More than 30 prospective studies involving more than 250 000 people have demonstrated that fasting TG concentrations are associated with an excess risk of coronary disease even after controlling for other risk factors.1 With the exception of patients with familial hypertriglyceridemia, there is little doubt that TG concentration represents an important risk factor. The population-based report by Ford et al is of interest because it demonstrates that this risk factor is found in more than 30% of the population.
Should hypertriglyceridemia be treated, and if so, how? Several authors have advocated pharmacologic therapy and have cited the NCEP report.2 However, the NCEP report advocates pharmacologic treatment only for TG concentrations higher than 500 mg/dL. The report advocates lifestyle change for TG concentrations between 150 and 500 mg/dL and says that pharmacologic therapy can be considered in high-risk persons in this group.
It should . . . [Full Text of this Article]
AUTHOR INFORMATION
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati  Twitter
What's this?
RELATED ARTICLE
Hypertriglyceridemia and Its Pharmacologic Treatment Among US Adults
Earl S. Ford, Chaoyang Li, Guixiang Zhao, William S. Pearson, and Ali H. Mokdad
Arch Intern Med. 2009;169(6):572-578.
ABSTRACT
| FULL TEXT
|
